179 related articles for article (PubMed ID: 24929675)
1. Ado-trastuzumab emtansine-associated telangiectasias in metastatic breast cancer: a case series.
Sibaud V; Niec RE; Schindler K; Busam KJ; Roché H; Modi S; Delord JP; Lacouture ME
Breast Cancer Res Treat; 2014 Jul; 146(2):451-6. PubMed ID: 24929675
[TBL] [Abstract][Full Text] [Related]
2. Ado-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer.
Baron JM; Boster BL; Barnett CM
J Oncol Pharm Pract; 2015 Apr; 21(2):132-42. PubMed ID: 24682654
[TBL] [Abstract][Full Text] [Related]
3. Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Metastatic Breast Cancer Previously Treated With Chemotherapy and 2 or More HER2-Targeted Agents: Results From the T-PAS Expanded Access Study.
Yardley DA; Krop IE; LoRusso PM; Mayer M; Barnett B; Yoo B; Perez EA
Cancer J; 2015; 21(5):357-64. PubMed ID: 26389758
[TBL] [Abstract][Full Text] [Related]
4. Trastuzumab emtansine in human epidermal growth factor receptor 2-positive metastatic breast cancer: an integrated safety analysis.
Diéras V; Harbeck N; Budd GT; Greenson JK; Guardino AE; Samant M; Chernyukhin N; Smitt MC; Krop IE
J Clin Oncol; 2014 Sep; 32(25):2750-7. PubMed ID: 25024070
[TBL] [Abstract][Full Text] [Related]
5. Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer.
Krop I; Winer EP
Clin Cancer Res; 2014 Jan; 20(1):15-20. PubMed ID: 24135146
[TBL] [Abstract][Full Text] [Related]
6. Nursing perspectives on trastuzumab emtansine for the treatment of metastatic breast cancer.
Bourdeanu L; Luu T
Clin J Oncol Nurs; 2013 Oct; 17(5):E58-62. PubMed ID: 24080060
[TBL] [Abstract][Full Text] [Related]
7. Acute Pancreatitis Associated With Ado-Trastuzumab Emtansine.
Muzaffar M; Jia J; Liles D; Naveed M; Kumari A
Am J Ther; 2016; 23(2):e572-4. PubMed ID: 25756468
[TBL] [Abstract][Full Text] [Related]
8. T-DM1-related telangiectasias: a potential role in secondary bleeding events.
Sibaud V; Vigarios E; Combemale P; Lamant L; Lacouture ME; Lacaze JL; Dalenc F; Delord JP
Ann Oncol; 2015 Feb; 26(2):436-7. PubMed ID: 25403586
[No Abstract] [Full Text] [Related]
9. Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer.
Boyraz B; Sendur MA; Aksoy S; Babacan T; Roach EC; Kizilarslanoglu MC; Petekkaya I; Altundag K
Curr Med Res Opin; 2013 Apr; 29(4):405-14. PubMed ID: 23402224
[TBL] [Abstract][Full Text] [Related]
10. Treatment of HER2 positive advanced breast cancer with T-DM1: A review of the literature.
Martínez MT; Pérez-Fidalgo JA; Martín-Martorell P; Cejalvo JM; Pons V; Bermejo B; Martín M; Albanell J; Lluch A
Crit Rev Oncol Hematol; 2016 Jan; 97():96-106. PubMed ID: 26318092
[TBL] [Abstract][Full Text] [Related]
11. Trastuzumab emtansine for the treatment of HER2-positive metastatic breast cancer.
Haddley K
Drugs Today (Barc); 2013 Nov; 49(11):701-15. PubMed ID: 24308017
[TBL] [Abstract][Full Text] [Related]
12. Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.
Hurvitz SA; Dirix L; Kocsis J; Bianchi GV; Lu J; Vinholes J; Guardino E; Song C; Tong B; Ng V; Chu YW; Perez EA
J Clin Oncol; 2013 Mar; 31(9):1157-63. PubMed ID: 23382472
[TBL] [Abstract][Full Text] [Related]
13. T-DM1 as a New Treatment Option for Patients with Metastatic HER2-positive Breast Cancer in Clinical Practice.
Michel LL; Bermejo JL; Gondos A; Marmé F; Schneeweiss A
Anticancer Res; 2015 Sep; 35(9):5085-90. PubMed ID: 26254411
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.
Burris HA; Rugo HS; Vukelja SJ; Vogel CL; Borson RA; Limentani S; Tan-Chiu E; Krop IE; Michaelson RA; Girish S; Amler L; Zheng M; Chu YW; Klencke B; O'Shaughnessy JA
J Clin Oncol; 2011 Feb; 29(4):398-405. PubMed ID: 21172893
[TBL] [Abstract][Full Text] [Related]
15. [Antibody-drug conjugates in oncology: from the concept to trastuzumab emtansine (T-DM1)].
Gonçalves A; Trédan O; Villanueva C; Dumontet C
Bull Cancer; 2012 Dec; 99(12):1183-91. PubMed ID: 23247898
[TBL] [Abstract][Full Text] [Related]
16. [New Hope for HER2-Positive Metastatic Breast Cancer Treatment: Trastuzumab Emtansine (T-DM1) From the Perspective of Nursing Care].
Kuo HH; Chen WW
Hu Li Za Zhi; 2016 Oct; 63(5):121-126. PubMed ID: 27699747
[TBL] [Abstract][Full Text] [Related]
17. Ado-trastuzumab Emtansine (T-DM1): an antibody-drug conjugate (ADC) for HER2-positive breast cancer.
Lambert JM; Chari RV
J Med Chem; 2014 Aug; 57(16):6949-64. PubMed ID: 24967516
[TBL] [Abstract][Full Text] [Related]
18. Trastuzumab emtansine: a review of its use in patients with HER2-positive advanced breast cancer previously treated with trastuzumab-based therapy.
Dhillon S
Drugs; 2014 Apr; 74(6):675-86. PubMed ID: 24659374
[TBL] [Abstract][Full Text] [Related]
19. Safety and Efficacy of Trastuzumab Emtansine in Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: a Meta-analysis.
Shen K; Ma X; Zhu C; Wu X; Jia H
Sci Rep; 2016 Mar; 6():23262. PubMed ID: 26979925
[TBL] [Abstract][Full Text] [Related]
20. Safety Profile and Costs of Related Adverse Events of Trastuzumab Emtansine for the Treatment of HER2-Positive Locally Advanced or Metastatic Breast Cancer Compared to Capecitabine Plus Lapatinib from the Perspective of the Canadian Health-Care System.
Piwko C; Prady C; Yunger S; Pollex E; Moser A
Clin Drug Investig; 2015 Aug; 35(8):487-93. PubMed ID: 26123628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]